mots-c mastery course
Unit 7 of 10

WADA, doping, and the regulatory landscape

why MOTS-c is on the 2026 Prohibited List under S4.5.2

a substance with a banned-in-sport label and a category-2 compounding flag

Two regulatory authorities have already weighed in on MOTS-c, and neither has approved it. One bans it from sport, the other flags it for compounding-safety review. This unit walks through both anchors, what they actually say, and what they mean in practice.

WADA 2026 prohibited list -- S4.5.2

"metabolic modulators ... including but not limited to AMPK activators (e.g., AICAR, SR9009) and PPARĪ“ agonists (e.g., GW1516), and the mitochondrial-derived peptide MOTS-c."

section S4.5.2, hormone and metabolic modulators -- prohibited at all times, in and out of competition.

the WADA side -- banned in sport

The 2026 WADA Prohibited List places MOTS-c under category S4.5.2 -- metabolic modulators. The same category captures other compounds whose mechanism centers on AMPK activation: AICAR itself, GW1516, and SR9009. The MOTS-c entry is recent, current, and applies year-round for athletes subject to WADA-aligned testing.

the FDA side -- category 2 compounding flag

In the United States, the FDA places MOTS-c on its Category 2 bulk drug substances list under compounding policy. This is not an approval and not a ban; it is a regulatory signal that the agency considers compounding from bulk material to raise significant safety concerns absent further evaluation. There is no FDA-approved MOTS-c drug product.

The two regulatory anchors to memorize: 2026 WADA Prohibited List, S4.5.2 (banned in sport) and FDA Category 2 bulk drug substances (compounding risk category). Neither is an approval.

at a glance

the load-bearing facts for this unit.

S4.5.2
WADA category -- metabolic modulators / AMPK activators
2026
year of the current Prohibited List entry
Category 2
FDA bulk drug substances compounding designation
not approved
no FDA-approved MOTS-c product exists

regulatory status map

click each jurisdiction to see the current MOTS-c regulatory posture and the controlling document. the takeaway is that MOTS-c sits in a uniform restrictive posture across major sport and drug regulators -- WADA S4.5.2 ban, FDA Category 2 compounding flag, no approved indication anywhere -- so anyone framing it as "just a research peptide" is ignoring an active and well-documented regulatory landscape.

regulatory status map

key terms

definitions you will encounter throughout this unit.

WWADAregulatory
The World Anti-Doping Agency. International body that maintains the annual Prohibited List of substances banned from competitive sport across most Olympic and many non-Olympic federations.
SS4.5.2regulatory
The section of the WADA Prohibited List covering metabolic modulators, specifically AMPK activators. The section where MOTS-c is listed in 2026.
Iin-competitionregulatory
A WADA prohibited-list category whose ban applies only during a defined competition window. MOTS-c falls under a substance-class that is prohibited at all times, not in-competition-only.
CCategory 2regulatory
An FDA designation for bulk drug substances about which the agency has raised significant safety concerns and for which compounding without further evaluation is not appropriate. MOTS-c is on this list.
AAAFsafety
Adverse analytical finding. The formal term for a positive doping test result in WADA terminology. An AAF for a substance under S4.5.2 typically triggers an anti-doping rule violation proceeding.
TTUEregulatory
Therapeutic use exemption. A process by which an athlete can apply for permission to use a prohibited substance for a documented medical condition. TUE approvals for AMPK activators are rare and require a strong clinical justification.

simple version first, advanced detail below

the plain-English read on this unit's mechanism, with technical depth on demand.

if you compete -- it is banned

If you compete under WADA-aligned rules, MOTS-c is banned in sport. That is current as of the 2026 Prohibited List, not a future or proposed change. The listing sits under S4.5.2, the section for metabolic modulators and AMPK activators, alongside AICAR itself and several other compounds with the same general mechanism.

if you prescribe -- it is not approved

Separately, in the United States the FDA has placed MOTS-c on Category 2 of its bulk drug substances list under compounding policy, meaning the agency considers compounding from raw MOTS-c material to raise significant safety concerns without further evaluation. Neither status is an approval; both shape the legal and clinical landscape in real ways.

Aadvanced: how a substance gets onto S4.5.2term
WADA's annual List Expert Group reviews candidate substances against three criteria: (1) the substance has the potential to enhance performance; (2) the substance presents an actual or potential health risk to the athlete; (3) use of the substance violates the spirit of sport. A substance must meet at least two of the three. AMPK activators meet (1) because of the mechanistic overlap with exercise adaptations; meet (3) by definition for this class; and meet (2) inconsistently depending on the specific compound and its safety dataset. MOTS-c meets enough of the criteria, based largely on the preclinical performance data (Reynolds 2021), to justify the S4.5.2 listing.
Aadvanced: testing methodology for peptide modulatorsterm
Detecting peptide-class substances in athlete samples relies on liquid chromatography-mass spectrometry (LC-MS/MS) targeted to the peptide's specific mass and fragmentation pattern, often with a prior immunoaffinity enrichment step. For endogenous-like peptides such as MOTS-c, the detection challenge is distinguishing exogenous administration from elevated endogenous production. WADA-accredited labs use isotope-ratio mass spectrometry, longitudinal athlete biological passport patterns, and sometimes specific glycoform or impurity profiles characteristic of synthetic versus endogenous material. The exact validated methodology for MOTS-c at WADA-accredited labs is not fully public.

WADA AMPK-activator class members

how the pieces line up against each other.

MOTS-c

  • 16-residue mitochondrial peptide
  • activates AMPK indirectly via AICAR accumulation
  • preclinical performance and metabolic data
  • on 2026 Prohibited List under S4.5.2

AICAR (acadesine)

  • small-molecule AMP analog
  • directly activates AMPK via the gamma-subunit pocket
  • studied for ischemia-reperfusion and metabolic indications
  • banned by WADA; never reached metabolic approval

GW1516, SR9009

  • oral PPAR-delta and REV-ERB modulators
  • engage exercise-adaptation transcriptional programs
  • never approved -- safety signals halted development
  • both banned under WADA S4.5.2-adjacent categories
Do not assume "preclinical-only" means "not actually banned." WADA bans based on mechanism and performance potential, not on regulatory approval status. MOTS-c is on the list specifically because of its preclinical AMPK-activation profile, not because it is an approved drug.